Eosinophilic esophagitis (EoE), a chronic disease that causes inflammation and damage to the esophagus, can be tricky to diagnose accurately. This is due to the fact that some of the symptoms of ...

Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...

The condition is called eosinophilic esophagitis (EoE), and while physicians like myself are learning more about it everyday, the cause remains unknown, and incidence continues to increase in the ...

The patient had a clinically established eosinophilic esophagitis milk allergy. Conventional T cells that expressed eoeTCR-4 proliferated when researchers stimulated them with recombinant beta-casein.

Among patients with eosinophilic esophagitis (EoE), both those who are responsive to proton pump inhibitors (PPIs) and those who are unresponsive to PPI treatment share similar esophageal protein ...

Chehade addresses challenges in eosinophilic esophagitis (EoE) treatment, noting the lack of highly effective therapies and predictive factors. Pediatric patients face developmental challenges ...

Post-treatment endoscopy reveals more inflammation among individuals with EoE who used cannabis. Cannabis users with eosinophilic esophagitis (EoE) initially show milder endoscopic symptoms at ...

Dupixent can be used to treat eosinophilic esophagitis in adults and certain children. This article covers topics such as how long to use Dupixent, how the drug works, and side effects.

Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for ...

Chehade discusses promising emerging treatments for eosinophilic esophagitis (EoE), including biologics like dupilumab, tezepelumab, and barzolvolimab. Additional options like APT-1011 and ...

The presentation will highlight encouraging results of APT-1011 (fluticasone propionate orally disintegrating tablet) in the FLUTE-2 Phase 3 clinical study in Eosinophilic Esophagitis (EoE).